Philip S Wells

List of Publications by Year
in descending order

190 papers	24,360 citations	71102 41 h-index	7160 153 g-index
195 all docs	195 docs citations	195 times ranked	15240 citing authors

#	Article	IF	Citations
1	Antithrombotic Therapy for VTE Disease. Chest, 2016, 149, 315-352.	0.8	4,060
2	Antithrombotic Therapy for VTE Disease. Chest, 2012, 141, e419S-e496S.	0.8	3,745
3	Oral Rivaroxaban for Symptomatic Venous Thromboembolism. New England Journal of Medicine, 2010, 363, 2499-2510.	27.0	2,807
4	Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. New England Journal of Medicine, 2012, 366, 1287-1297.	27.0	2,080
5	Evaluation of D-Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis. New England Journal of Medicine, 2003, 349, 1227-1235.	27.0	1,329
6	A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism. New England Journal of Medicine, 1999, 340, 901-907.	27.0	1,052
7	Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism. New England Journal of Medicine, 2003, 349, 631-639.	27.0	728
8	Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. New England Journal of Medicine, 2019, 380, 711-719.	27.0	614
9	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. New England Journal of Medicine, 2017, 376, 1211-1222.	27.0	577
10	Diagnosis of DVT. Chest, 2012, 141, e351S-e418S.	0.8	570
11	Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019. Chest, 2020, 158, 1143-1163.	0.8	531
12	Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet, The, 2014, 383, 880-888.	13.7	425
13	Does This Patient Have Deep Vein Thrombosis?. JAMA - Journal of the American Medical Association, 2006, 295, 199.	7.4	403
14	Antithrombotic Therapy for VTE Disease. Chest, 2021, 160, e545-e608.	0.8	357
15	Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. New England Journal of Medicine, 2018, 378, 699-707.	27.0	294
16	Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology,the, 2014, 1, e37-e46.	4.6	244
17	Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2018, 320, 1583.	7.4	224
18	Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet, The, 2014, 384, 1673-1683.	13.7	210

#	Article	IF	Citations
19	A Novel and Rapid Whole-Blood Assay for D-Dimer in Patients With Clinically Suspected Deep Vein Thrombosis. Circulation, 1995, 91, 2184-2187.	1.6	203
20	Functional and Exercise Limitations After a First Episode of Pulmonary Embolism. Chest, 2017, 151, 1058-1068.	0.8	192
21	Development of a Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism in Patients With Cancer-Associated Venous Thromboembolism. Circulation, 2012, 126, 448-454.	1.6	179
22	Treatment of Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2014, 311, 717.	7.4	176
23	A Randomized Trial Comparing 2 Low-Molecular-Weight Heparins for the Outpatient Treatment of Deep Vein Thrombosis and Pulmonary Embolism. Archives of Internal Medicine, 2005, 165, 733.	3.8	156
24	Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood, 2016, 127, 1417-1425.	1.4	156
25	Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin. Thrombosis and Haemostasis, 1994, 71, 300-304.	3.4	150
26	Outpatient treatment of symptomatic pulmonary embolism: A systematic review and meta-analysis. Thrombosis Research, 2013, 132, 515-519.	1.7	131
27	Clinical and Safety Outcomes Associated With Treatment of Acute Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2014, 312, 1122.	7.4	126
28	Long-range epigenetic regulation is conferred by genetic variation located at thousands of independent loci. Nature Communications, 2015, 6, 6326.	12.8	115
29	The Outpatient Bleeding Risk Index. Archives of Internal Medicine, 2003, 163, 917.	3.8	114
30	Quality of Life, Dyspnea, and Functional Exercise Capacity Following a First Episode of Pulmonary Embolism: Results of the ELOPE Cohort Study. American Journal of Medicine, 2017, 130, 990.e9-990.e21.	1.5	107
31	Application of a Novel and Rapid Whole Blood Assay for D-Dimer in Patients with Clinically Suspected Pulmonary Embolism. Thrombosis and Haemostasis, 1995, 73, 035-038.	3.4	94
32	Factor XIII Val34Leu Variant Is Protective against Venous Thromboembolism: A HuGE Review and Meta-Analysis. American Journal of Epidemiology, 2006, 164, 101-109.	3.4	84
33	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Advances, 2018, 2, 788-796.	5.2	71
34	Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding. Chest, 2017, 152, 81-91.	0.8	68
35	The diagnosis and treatment of venous thromboembolism. Hematology American Society of Hematology Education Program, 2013, 2013, 457-463.	2.5	60
36	Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism. Annals of Internal Medicine, 2021, 174, 1420-1429.	3.9	60

#	Article	IF	Citations
37	Factors that predict thrombosis in relatives of patients with venous thromboembolism. Blood, 2014, 124, 2124-2130.	1.4	59
38	Thromboprophylaxis in Patients With COVID-19. Chest, 2022, 162, 213-225.	0.8	58
39	Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology,the, 2016, 3, e228-e236.	4.6	55
40	Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism. American Journal of Medicine, 2017, 130, 588-595.	1.5	45
41	Diagnosis of Venous Thromboembolism: 20 Years of Progress. Annals of Internal Medicine, 2018, 168, 131.	3.9	43
42	Safety and Efficacy of Methods for Reducing Perioperative Allogeneic Transfusion: A Critical Review of the Literature. American Journal of Therapeutics, 2002, 9, 377-388.	0.9	42
43	Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in ambulatory cancer patients at intermediate-high risk for venous thrombosis. Thrombosis Research, 2015, 136, 1099-1102.	1.7	41
44	Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2019, 17, 2141-2151.	3.8	41
45	Advances in the Diagnosis of Venous Thromboembolism. Journal of Thrombosis and Thrombolysis, 2006, 21, 31-40.	2.1	40
46	Endovascular cooling catheter related thrombosis in patients undergoing therapeutic hypothermia for out of hospital cardiac arrest. Resuscitation, 2014, 85, 1354-1358.	3.0	38
47	Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. BMJ, The, 2021, 373, n1205.	6.0	38
48	Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study. Thrombosis Research, 2018, 163, 41-46.	1.7	36
49	Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: A multi-national cohort. Thrombosis Research, 2016, 143, 152-158.	1.7	35
50	Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation. Annals of Internal Medicine, 2022, 175, 29-35.	3.9	33
51	Blood triglyceride levels are associated with DNA methylation at the serine metabolism gene PHGDH. Scientific Reports, 2017, 7, 11207.	3.3	32
52	Treatment of Pulmonary Embolism With Rivaroxaban: Outcomes by Simplified Pulmonary Embolism Severity Index Score from a Post Hoc Analysis of the <scp>EINSTEIN PE</scp> Study. Academic Emergency Medicine, 2015, 22, 299-307.	1.8	31
53	Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology,the, 2016, 3, e437-e445.	4.6	29
54	Surgical Treatment of Chronic Thromboembolic Pulmonary Hypertension. Canadian Respiratory Journal, 2000, 7, 49-57.	1.6	28

#	Article	IF	Citations
55	Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial. Thrombosis Research, 2018, 164, S124-S129.	1.7	28
56	Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study. Thrombosis Research, 2018, 162, 104-109.	1.7	27
57	VTE Prophylaxis in Critically Ill Adults. Chest, 2022, 161, 418-428.	0.8	27
58	Safety and Efficiency of Diagnostic Strategies for Ruling Out Pulmonary Embolism in Clinically Relevant Patient Subgroups. Annals of Internal Medicine, 2022, 175, 244-255.	3.9	27
59	Diagnosis of pulmonary embolism: when is imaging needed?. Clinics in Chest Medicine, 2003, 24, 13-28.	2.1	26
60	Clinical Decision Rules and D-dimer in Venous Thromboembolism: Current controversies and future research priorities. Thrombosis Research, 2014, 134, 763-768.	1.7	25
61	Comparison of Four Bleeding Risk Scores to Identify Rivaroxabanâ€treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding. Academic Emergency Medicine, 2016, 23, 144-150.	1.8	25
62	Bleeding risk in patients with unprovoked venous thromboembolism: A critical appraisal of clinical prediction scores. Thrombosis Research, 2017, 152, 52-60.	1.7	25
63	Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE. Chest, 2016, 150, 1059-1068.	0.8	24
64	D-Dimer for Pulmonary Embolism. JAMA - Journal of the American Medical Association, 2015, 313, 1668.	7.4	21
65	Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research, 2018, 162, 7-14.	1.7	20
66	Timing of vitamin K antagonist re-initiation following intracranial hemorrhage in mechanical heart valves: Systematic review and meta-analysis. Thrombosis Research, 2016, 144, 152-157.	1.7	19
67	Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis. Haematologica, 2020, 105, 1436-1442.	3.5	19
68	Longâ€term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2021, 19, 2801-2813.	3.8	19
69	Ruling out pulmonary embolism across different healthcare settings: A systematic review and individual patient data meta-analysis. PLoS Medicine, 2022, 19, e1003905.	8.4	19
70	The Diagnosis of Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2012, 38, 691-701.	2.7	18
71	DNA methylation age is associated with an altered hemostatic profile in a multiethnic meta-analysis. Blood, 2018, 132, 1842-1850.	1.4	16
72	Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants. American Journal of Kidney Diseases, 2020, 76, 311-320.	1.9	16

#	Article	IF	Citations
73	Benefit of early discharge among patients with low-risk pulmonary embolism. PLoS ONE, 2017, 12, e0185022.	2.5	16
74	Pulmonary Embolism: A Clinician's Perspective. Seminars in Nuclear Medicine, 2008, 38, 404-411.	4.6	15
75	The value of sPESI for risk stratification in patients with pulmonary embolism. Journal of Thrombosis and Thrombolysis, 2019, 48, 149-157.	2.1	15
76	Alignment to ACCP Prophylaxis Guidelines and VTE Outcomes in THR and TKR Patients. Blood, 2008, 112, 170-170.	1.4	15
77	Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy. Thrombosis Journal, 2014, 12, 26.	2.1	14
78	Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. Internal and Emergency Medicine, 2017, 12, 311-318.	2.0	14
79	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. Thrombosis Research, 2017, 149, 29-37.	1.7	14
80	Analysis of venous thromboprophylaxis duration and outcomes in orthopedic patients. American Journal of Managed Care, 2010, 16, 857-63.	1.1	14
81	Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 830-837.	1.7	13
82	The Role of Qualitative D-Dimer Assays, Clinical Probability, and Noninvasive Imaging Tests for the Diagnosis of Deep Vein Thrombosis and Pulmonary Embolism. Seminars in Vascular Medicine, 2005, 05, 340-350.	2.1	12
83	Rivaroxaban shows promise as effective therapy for cancer patients with venous thromboembolic disease. Thrombosis Research, 2017, 152, 4-6.	1.7	12
84	Longâ€term risk of recurrent venous thromboembolism after a first contraceptiveâ€related event: Data from REVERSE cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 1526-1532.	3.8	12
85	Practical application of the 10-mg warfarin initiation nomogram. Blood Coagulation and Fibrinolysis, 2009, 20, 403-408.	1.0	11
86	An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. Journal of Medical Economics, 2011, 14, 238-244.	2.1	11
87	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Thrombosis Research, 2018, 168, 121-129.	1.7	11
88	Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial. Thrombosis Research, 2021, 202, 151-154.	1.7	11
89	Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding. Thrombosis Research, 2019, 182, 12-19.	1.7	10
90	Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study. Thrombosis Research, 2020, 191, S31-S36.	1.7	10

#	Article	IF	Citations
91	Genetically defined elevated homocysteine levels do not result in widespread changes of DNA methylation in leukocytes. PLoS ONE, 2017, 12, e0182472.	2.5	10
92	Safety of Primary Thromboprophylaxis Using Apixaban in Ambulatory Cancer Patients with Intracranial Metastatic Disease or Primary Brain Tumors. Thrombosis and Haemostasis, 2019, 119, 1886-1887.	3.4	9
93	D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer. Oncologist, 2020, 25, 1075-1083.	3.7	9
94	Development of A Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism In Patients with Cancer-Associated Venous Thromboembolism. Blood, 2010, 116, 475-475.	1.4	9
95	Costâ€"utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer. Cmaj, 2021, 193, E1551-E1560.	2.0	9
96	The factor XIII Val34Leu polymorphism: is it protective against idiopathic venous thromboembolism?. Blood Coagulation and Fibrinolysis, 2006, 17, 533-538.	1.0	8
97	Timing of anticoagulant re-initiation following intracerebral hemorrhage in mechanical heart valves: Survey of neurosurgeons and thrombosis experts. Clinical Neurology and Neurosurgery, 2017, 154, 23-27.	1.4	8
98	Venous thromboembolism prevention in intracerebral hemorrhage: A systematic review and network meta-analysis. PLoS ONE, 2020, 15, e0234957.	2.5	8
99	Safety and efficacy of apixaban thromboprophylaxis in cancer patients with metastatic disease: A post-hoc analysis of the AVERT trial. Thrombosis Research, 2021, 197, 13-15.	1.7	8
100	Computed Tomographic Pulmonary Angiography for Pulmonary Embolism. JAMA - Journal of the American Medical Association, 2015, 314, 74.	7.4	7
101	Nonleg Venous Thrombosis in Critically Ill Adults. JAMA - Journal of the American Medical Association, 2015, 313, 411.	7.4	7
102	Association of Splanchnic Vein Thrombosis on Survival: 15â€Year Institutional Experience With 1561 Cases. Journal of the American Heart Association, 2020, 9, e016600.	3.7	7
103	Applying rigorous eligibility criteria to studies evaluating prognostic utility of serum biomarkers in pulmonary embolism: A systematic review and meta-analysis. Thrombosis Research, 2020, 195, 195-208.	1.7	7
104	Double Blind Randomized Control Trial of Postoperative Low Molecular Weight Heparin Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2). Blood, 2018, 132, 424-424.	1.4	7
105	"Post-Pulmonary Embolism Syndrome" after a First Episode of PE: Results of the E.L.O.P.E. Study. Blood, 2015, 126, 650-650.	1.4	7
106	Outcomes of Pulmonary Embolism In Surgical Patients: A Retrospective Cohort Study. Blood, 2010, 116, 3180-3180.	1.4	7
107	Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism. Blood Advances, 2022, 6, 4605-4616.	5.2	7
108	Feasibility of blinding in a randomized controlled trial comparing preoperative autologous blood donation and acute normovolemic hemodilution in adult cardiac surgery. Transfusion, 2000, 40, 1058-1062.	1.6	6

#	Article	IF	Citations
109	Outcomes associated with observation stays versus inpatient admissions for pulmonary embolism. Journal of Thrombosis and Thrombolysis, 2016, 42, 513-519.	2.1	6
110	Homocysteine levels associate with subtle changes in leukocyte DNA methylation: an epigenome-wide analysis. Epigenomics, 2017, 9, 1403-1422.	2.1	6
111	Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE. Clinical Therapeutics, 2017, 39, 1396-1408.	2.5	6
112	Management of direct oral anticoagulant associated bleeding: Results of a multinational survey. Thrombosis Research, 2018, 163, 19-21.	1.7	6
113	Sex Differences in Patients With Occult Cancer After Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 489-495.	1.7	6
114	The impact of Stress Management and Resilience Training (SMART) on academic physicians during the implementation of a new Health Information System: An exploratory randomized controlled trial. PLoS ONE, 2022, 17, e0267240.	2.5	6
115	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. TH Open, 2018, 02, e1-e7.	1.4	5
116	A Meta-Analysis to Determine the Risk of Heparin Induced Thrombocytopenia (HIT) and Isolated Thrombocytopenia in Prophylaxis Studies Comparing Unfractioneted Heparin (UFH) and Low Molecular Weight Heparin (LMWH).. Blood, 2004, 104, 2587-2587.	1.4	5
117	Efficacy and safety of primary thromboprophylaxis for the prevention of venous thromboembolism in patients with cancer and a central venous catheter: A systematic review and meta-analysis. Thrombosis Research, 2021, 208, 58-65.	1.7	5
118	Ximelagatran in Major Orthopedic Surgery: A Systematic Review and Meta-Analysis of Efficacy and Safety.. Blood, 2005, 106, 913-913.	1.4	5
119	N-terminal of prohormone brain natriuretic peptide predicts functional limitation one year following pulmonary embolism: Results from the ELOPE study. Thrombosis Research, 2017, 153, 47-49.	1.7	4
120	Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vsÂAspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population. Chest, 2018, 154, 1371-1378.	0.8	4
121	Predictive analytics by deep machine learning: A call for nextâ€gen tools to improve health care. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 181-182.	2.3	4
122	Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: a post-hoc analysis of the avert trial. Journal of Thrombosis and Thrombolysis, 2021, 51, 720-724.	2.1	4
123	A cross-sectional study of the interrelationship between burnout, empathy and resilience in academic physicians. Psychology, Health and Medicine, 2022, 27, 1813-1820.	2.4	4
124	A Pilot Study of Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombois of the Upper Extremity (UEDVT).. Blood, 2006, 108, 878-878.	1.4	4
125	Rivaroxaban for Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia Study. Blood, 2015, 126, 3468-3468.	1.4	4
126	A Prospective Cohort Study of Upper Extremity Deep Vein Thrombosis. Blood, 2015, 126, 893-893.	1.4	4

#	Article	IF	Citations
127	Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial. Thrombosis Research, 2021, 208, 79-82.	1.7	4
128	Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism. Journal of Health Economics and Outcomes Research, 2019, 6, 84-94.	1.2	4
129	Overview and comparison of D-dimer assay kits for DVT and PE. Clinical Advances in Hematology and Oncology, 2004, 2, 160, 178.	0.3	4
130	Growth Differentiation Factor-15, High-Sensitivity Cardiac Troponin T, and N-Terminal pro-B-type Natriuretic Peptide for Predicting Risk of Venous Thromboembolism in Ambulatory Cancer Patients Receiving Chemotherapy. Thrombosis and Haemostasis, 2022, 122, 1169-1176.	3.4	4
131	External validation of a claims-based and clinical approach for predicting post-pulmonary embolism outcomes among United States veterans. Internal and Emergency Medicine, 2017, 12, 613-619.	2.0	3
132	Risk Stratification of Pulmonary Embolism. Critical Care Clinics, 2020, 36, 437-448.	2.6	3
133	Safety of using direct oral anticoagulants in the diagnostic workup of outpatients with suspicion of acute venous thromboembolism. Haematologica, 2020, 105, e307-e309.	3.5	3
134	Evaluation of Definitions for Oral Anticoagulantâ€"Associated Major Bleeding: A Population-Based Cohort Study. Blood, 2018, 132, 426-426.	1.4	3
135	Computerized Tomographic Pulmonary Angiography Compared with Ventilation-Perfusion Lung Scanning as Inital Diagnostic Modality for Patients with Suspected Pulmonary Embolism: A Randomized Controlled Trial.. Blood, 2005, 106, 1619-1619.	1.4	3
136	Inflammation Markers and The Risk Of Post Thrombotic Syndrome: Results From The Bio-Sox Study. Blood, 2013, 122, 36-36.	1.4	3
137	Prediction of Bleeding Risk in Patients on Extended Oral Anticoagulation for Venous Thromboembolism. Blood, 2016, 128, 139-139.	1.4	3
138	Safety and efficacy of apixaban thromboprophylaxis in ambulatory cancer patients according to renal function: A subgroup analysis of the AVERT trial. Thrombosis Research, 2022, 211, 85-87.	1.7	3
139	Standardization of risk prediction model reporting in cancerâ€associated thrombosis: Communication from the ISTHÂSSC subcommittee on hemostasis and malignancy. Journal of Thrombosis and Haemostasis, 2022, 20, 1920-1927.	3.8	3
140	Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. International Journal of Clinical Practice, 2017, 71, e12915.	1.7	2
141	Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism. Clinical Therapeutics, 2017, 39, 1426-1436.e2.	2.5	2
142	Observation management of pulmonary embolism and agreement with claims-based and clinical risk stratification criteria in United States patients: a retrospective analysis. BMC Pulmonary Medicine, 2017, 17, 37.	2.0	2
143	Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results. Journal of Medical Economics, 2018, 21, 587-594.	2.1	2
144	Regarding the necessity of an updated meta-analysis on the prognostic value of serum biomarkers in patients with pulmonary embolism. Thrombosis Research, 2019, 176, 8-10.	1.7	2

#	Article	IF	Citations
145	Extended therapy for unprovoked venous thromboembolism: when is it indicated?. Blood Advances, 2019, 3, 499-499.	5.2	2
146	Indirect Comparisons of Rivaroxaban Versus Alternative Prophylaxes for the Prevention of VTE in Patients Undergoing Total Knee Replacement.. Blood, 2008, 112, 1292-1292.	1.4	2
147	A Systematic Review and Meta-Analysis of Proportions of Thrombosis and Bleeding in Patients Receiving Venous Thromboembolism (VTE) Prophylaxis After Orthopedic Surgery (OS). An Update.. Blood, 2009, 114, 3125-3125.	1.4	2
148	Predictors Of The Post-Thrombotic Syndrome In a Large Cohort Of Patients With Proximal DVT: Secondary Analysis Of The Sox Trial. Blood, 2013, 122, 460-460.	1.4	2
149	Post-Thrombotic Syndrome and Functional Disability in Patients with Upper Extremity Deep Vein Thrombosis: A Prospective Cohort Study. Blood, 2016, 128, 417-417.	1.4	2
150	Patients with Cancer Who Develop a First Venous Thromboembolic Event After Surgery Are at High Risk of Venous Thromboembolism Recurrence During the Anticoagulation Period. Blood, 2010, 116, 4202-4202.	1.4	2
151	Risk of Venous Thromboembolism Recurrence Among Rivaroxaban Treated Patients Who Continued Versus Discontinued Therapy: Analyses Among VTE Patients. Blood, 2016, 128, 144-144.	1.4	2
152	Evaluation of definitions for oral anticoagulant-associated major bleeding: A population-based cohort study. Thrombosis Research, 2022, 213, 57-64.	1.7	2
153	Dalteparin for pregnant women with thrombophilia â€“ Authors' reply. Lancet, The, 2015, 385, 690.	13.7	1
154	Outcomes associated with observation status versus inpatient management of pulmonary embolism patients anticoagulated with rivaroxaban. International Journal of Cardiology, 2016, 222, 846-849.	1.7	1
155	Leveraging cell type specific regulatory regions to detect SNPs associated with tissue factor pathway inhibitor plasma levels. Genetic Epidemiology, 2017, 41, 455-466.	1.3	1
156	Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study. Haematologica, 2019, 104, e474-e477.	3.5	1
157	Apixaban anti-Xa level monitoring in treatment of acute upper extremity deep vein thrombosis for patient on chronic hemodialysis: a case report. Thrombosis Journal, 2021, 19, 23.	2.1	1
158	Life dissatisfaction in Canadians aged 40 and above with cancer and mental health disorders: A crossâ€sectional study using the Canadian Community Health Survey. Cancer Medicine, 2021, 10, 7601-7609.	2.8	1
159	Trousseauâ€™s Syndrome Revisited: Should We Screen Extensively for Malignancy in Patients with Venous Thromboembolism? a Systematic Review and Meta-Analysis. Blood, 2008, 112, 403-403.	1.4	1
160	A Randomized, Controlled Two-Center Pilot Trial of a 6-Month Exercise Training Program to Treat the Post-Thrombotic Syndrome: The EXPO Pilot Trial.. Blood, 2009, 114, 3984-3984.	1.4	1
161	Dyspnea, Quality of Life and Walking Capacity during 1 Year Follow-up after a First Episode of Pulmonary Embolism: Results of the E.L.O.P.E. Study. Blood, 2015, 126, 750-750.	1.4	1
162	Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care. Journal of Health Economics and Outcomes Research, 2019, 6, 160-173.	1.2	1

#	Article	IF	Citations
163	Diagnostic Management Strategies in Patients with Suspected Deep Vein Thrombosis. , 0, , 315-327.		0
164	Therapies for Venous Thromboembolismâ€"Reply. JAMA - Journal of the American Medical Association, 2014, 311, 2543.	7.4	0
165	Inferior Vena Cava Filters in the Management of Venous Thromboembolismâ€"Reply. JAMA - Journal of the American Medical Association, 2019, 321, 1007.	7.4	0
166	Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer. Thrombosis Research, 2020, 196, 437-443.	1.7	0
167	Direct oral anticoagulant use in special populations. Current Opinion in Pulmonary Medicine, 2021, 27, 311-318.	2.6	0
168	Media portrayals of pulmonary embolism. Thrombosis Research, 2021, 206, 52-54.	1.7	0
169	Randomized Trial of Warfarin Nomograms. Annals of Internal Medicine, 2004, 140, 491.	3.9	0
170	Factor XIII Val34Leu Polymorphism Is Protective Against Venous Thromboembolism; a Meta-Analysis.. Blood, 2004, 104, 3512-3512.	1.4	0
171	Factor XIII Val34Leu Polymorphism and the Risk of Myocardial Infarction: A Meta-Analysis.. Blood, 2005, 106, 1637-1637.	1.4	0
172	The Effect of Dalteparin on Coagulation Activation during Pregnancy in Women with Thrombophilia: A Randomised Trial.. Blood, 2006, 108, 874-874.	1.4	0
173	Cost-Effectiveness of Rivaroxaban as VTE Prophylaxis after Total Hip Replacement in Canada.. Blood, 2008, 112, 1291-1291.	1.4	0
174	Practical Application of the 10 Mg Warfarin Initiation Nomogram. Blood, 2008, 112, 4054-4054.	1.4	0
175	VIDAS D-Dimer in Combination with Clinical Pre-Test Probability to Rule out Pulmonary Embolism. A Systematic Review of the Management Outcome Studies.. Blood, 2008, 112, 1811-1811.	1.4	0
176	Dose Escalation of Low Molecular Weight Heparin to Manage VTE Treatment Failure in Cancer Patients. Blood, 2008, 112, 4050-4050.	1.4	0
177	Outcome of Saddle Pulmonary Embolism: A Nested Case-Control Study.. Blood, 2010, 116, 1102-1102.	1.4	0
178	Validation of A Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism In Patients with Cancer-Associated Venous Thromboembolism. Blood, 2010, 116, 4209-4209.	1.4	0
179	Safety of Outpatient Treatment In Acute Pulmonary Embolism.. Blood, 2010, 116, 3796-3796.	1.4	0
180	Comparison of the Villalta Post Thrombotic Syndrome (PTS) Score in the Ipsilateral Versus Contralateral Leg After a First Unprovoked Deep Vein Thrombosis (DVT): Results From the REVERSE Study. Blood, 2011, 118, 1236-1236.	1.4	0

#	Article	IF	Citations
181	Frequency and Predictors of Post-Thrombotic Syndrome in Patients with a First, Unprovoked Deep Vein Thrombosis and No Prior Primary Venous Insufficiency: Results From the REVERSE Cohort Study,. Blood, 2011, 118, 3332-3332.	1.4	0
182	Performance Of The Simplified Pesi Score In Patients With Pulmonary Embolism Treated With Rivaroxaban Or Standard Therapy. Blood, 2013, 122, 1139-1139.	1.4	0
183	The Effectiveness Of 30-40 Mm Hg Compression Stockings To Treat Acute Leg Pain Associated With Proximal Deep Vein Thrombosis: Results From The Sox Randomized Controlled Trial. Blood, 2013, 122, 1126-1126.	1.4	0
184	Brain Natriuretic Peptide, Troponin and D-Dimer Levels in Relation to Long-Term Functional Outcome after a First Episode of Pulmonary Embolism: Results from the E.L.O.P.E. Study. Blood, 2015, 126, 649-649.	1.4	0
185	Do Genetic Contributors to Warfarin Responsiveness or Common Thrombophilias Influence the Risk of Major Bleeding in Patients on Extended Duration Vitamin K Antagonist (VKA) for Venous Thromboembolic Disease?. Blood, 2016, 128, 272-272.	1.4	0
186	External Validation of a Clinical and Claims-Based Approach for Predicting 90-Day Post-Pulmonary Embolism Outcomes Among US Veterans. Blood, 2016, 128, 533-533.	1.4	0
187	Reduced Costs and Length-of-Stay Associated with Rivaroxaban As Compared to Parenteral Bridging and Warfarin in Pulmonary Embolism Patients Managed in Observation Status. Blood, 2016, 128, 2337-2337.	1.4	0
188	Cost-Utility Analysis of Apixaban Compared to Usual Care for the Primary Thromboprophylaxis of Ambulatory Cancer Patients Initiating Chemotherapy. Blood, 2019, 134, 329-329.	1.4	0
189	Efficacy and Safety of Primary Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients with Cancer and Central Venous Catheter: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 2139-2139.	1.4	0
190	Apixaban Anti-Xa Level Monitoring in Treatment of Provoked Acute Upper Extremity Deep Vein Thrombosis for Patient on Dialysis: A Case Report. Blood, 2020, 136, 14-14.	1.4	0